used bi-specific antibodies (BiAbs) obtained from the fusion of two hybndomas producing antibodies to 13-D-galactosidase and hLh. The BiAb complexed with the enzyme (3-D-galactosidase was used as tracer in a double-determinant assay. We compared the assay involving the BlAb (Bi-EIA) with an immunoenzymatic assay (EIA) in which the same capture antibody was used but the tracer was an enzyme-conjugated hLH-specific monoclonal antibody produced by the same parental cell line used to produce the BiAb. conjugates are limited by the less reactivity of both antibody and enzyme activities, resulting in poor standardization and a significantly less-stable tracer than in the assays with unconjugated reagent. Low antibody affinity is the major limiting factor of final assay performance, resulting in lower sensitivity of EIAs than of immunoradiometric assays (IRMA5). Bi-specific antibodies, having the unique property of binding simultaneously to antigen and enzyme, can connect the two molecules under conditions in which there is no decrease in antibody or enzyme activity.
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To evaluate the possible applications of BiAbs to the development of clinical immunoassays and their potential advantages over the more "traditional" enzyme-antibody conjugates, we produced a panel of BiAbs able to recognize both human lutropin (hLH) and the enzyme /3-D-galactosidase (EC 3.2.1.23). One of the BiAbs (MLZL.3.55) was used to develop an EIA (Bi-EIA) in which a capture anti-hLH antibody was coupled to the solid phase.
MaterIals and Methods

Hybridoma production.
Mouse hybridoma cells producing monoclonal antibodies (ZL1-lb, IgG 1 isotype) to f3-D-galactosidase were kindly provided by Prof. R. S. Accolla (9). The mouse hybridoma producing monoclonal antibodies (MAL 1 and MAL 5) to hLH was prepared in our laboratory (10). The medium used was "RPM! 1640" (Gibco Labs., Grand Island, NY) supplemented with, per liter, 2 minol of L-glutamine, 10 mL of nonessential amino acids, 10 mL of sodium pyruvate, 50 pmol of 2-mercaptoethanol, and 100 mL of heat-inactivated fetal calf serum (Gibco). Production and screening of hybrid hybridomas. The hybridoma producing
anti--D-galactosidaae (ZL1-lbAgN2) was made resistant to 8-azaguanine (Sigma Chemical Co., St. Louis, MO 63178) and to antibiotic G418 (Gibco) as described elsewhere (6) . The hybridomas producing ZL1-lbAgN2 and the anti-hLH (MAL 1) were fused to each other in a one-to-one ratio, according to the procedures described by Galfr#{232} and Milstein (11) . Hybrid hybridomas were selected one day later by adding hypoxanthine (100
to the medium. After 18 days we screened the culture supernates for production of BiAbs by coating the enzyme onto the solid phase. Binding of the tracer BiAbs was revealed by '251-labeled hLH (Sclavo, Siena, Italy) as described below. Polystyrene beads (widerivatized polystyrene beads, 0.25-in, diameter; Pierce Eurochemie By, BA Oud-Beijerland, The Netherlands) were coated with -D-galactosidase (Grade Vifi, Sigma), 40 g/ mL, in 0.05 molJL sodium phosphate containing 0.1 mol of NaC1 per liter, pH 7.2 (PBS), for 18 h at 4 "C, at 250 p.L of solution per bead, and then saturated with PBS containing bovine serum albumin (BSA, Cohn Fraction V, Sigma), 10 WL.
After an 18-h incubation, the beads were washed extensively with PBS. For screening, we incubated 100 L of the cell culture supernates or parental hybridoma supernates alone and in combination (ZL1-lbAgN2 and MAL 1), with 100 pL of the iodinated tracer (25000 counts/mm) and polystyrene bead for 18 h at 4#{176}C.
After washing with PBS, total and bound radioactivity were counted in a gamma counter. Stable subclones producing the bispecific antibodies were obtained by a limiting dilution procedure (9 
14
.0 mg/cm3 for IgG). To remove the parental antibodies bearing the hLH activity, we added 2.7 mg (1800 U) of /3-u-galactosidase, free of aggregates, to 1.7 mg of purified MoAbs in a final volume of 5 mL of sodium phosphate buffer (10 mmoIJL, pH 6.8; buffer A) and incubating at 4 #{176}C for 24 h. The immunocomplexes were separated by HPLC on a Bio-Gel high-performance hydroxyapatite (RPHT) column (100 x 7.8 mm) with guard column (Bio-Rad). The chromatographic conditions involved step gradients between buffer A and buffer B (300 mmol/L sodium phosphate buffer, pH 6.8) as follows: from 0 to 10 mm 0% B; 10-20 mm from 0% to 5% B, 20-30 mm 5% B, 30-40 mm from 5% to 10% B, 40-SO mm 10% B, 50-60 mm from 10% to 15% B, 60-70 mm 15% B, and 70-120 mm from 15% to 100% B. The flow rate was 0.5 mL/min, detection was at 280 rim, absorbance units full scale = 0.08, and the sample volume was 1 mL. Peak fractions were checked for enzymatic activity with ONPG substrate as described above.
Using 100 1zL of serial dilutions of the fractions displaying enzyme activity, we tested for bi-specific monoclonal antibody activity. To 96-well microtiter plates that had been coated at room temperature for 2 h with hLH (1st !RP WHO 68/40) solution (5 .tg/mL, in PBS), 100 uL per well, then washed three times with PBS containing Tween 20 (Sigma), 0.5 mJJL, and saturated with a 5 g/L solution of casein in PBS, we added the enzyme-activity-containing fractions (100 pL per well, in duplicate) and incubated at room temperature for 2 h. After three washes, we added 100 p1 of ONPG solution to each well, then terminated the reaction after 30 mm at 37 #{176}C by adding 50 p1 of 2 mol/L Na2CO3 to each well and measured the absorbance of the o-nitrophenol. Negative controls for each fraction consisted of wells coated with casein only. EJA immunoassay procedure. This procedure has been described in a report on assay of lutropin (10). We used the same standards, solid phase, and biotinylated and labeled antibody as in the Bi-EIA. The anti-hLH monoclonal antibody MAL 1 conjugated with /3-D-galactosidase was tracer, and the assay was performed as described above for the Bi-EIA. Enzymatic activity was 10 or 20 U per well.
Correlation with other immunoassays. The reagent kits used to correlate the Bi-EIA with other immunoassays were as follows: LH-MAIA Clone (Ares Serono Diagnostics tivity of these three commercial immunoassays has been determined by the manufacturers in terms of value for zero standard plus two standard deviations. All kits were used according to the manufacturers' directions to determine the hLH concentration of 25 patients' sera, in duplicate.
Results
Production of bi-specific antibodies (BiAbs). In the first fusion, we fused the anti-3-D-galactosidase 8-azaguanine and G418-resistant hybridoma (ZL1-lbAgN2) with the anti-hLH hybridoma (MAL 1) at a one-to-one ratio. After 18 days of selection in HAT medium containing G418 we obtained392 growing clones (plating efficiency, 68.5%). We repeatedly screened all growing clones for bi-specific antibodies, as described previously. On the basis of reactivity, we selected five clones that were further subcloned by limiting dilution. One subclone from each clone was further expanded in vitro and then injected into pristane-treated mice to induce production of ascitic fluid. We selected the clone MLZL.3.55 for high-titer antibody production.
BiAb purification.
We first purified antibodies with different bi-specific activity had been purified. For the development of the Bi-ELA, we used the fractions obtained at 77.29 miii because they had the highest bi-specific activity.
Assay optimization. We set up a Bi-EIA, using as catcher the hLH-specific antibody MAL 5 and as tracer the HPLC fraction obtained from HPLC purification of BiAbs/13-gai immunocomplexes.
We calibrated different batches of BlAb/p-gal separately against a constant solid-phase concentration to determine the optimum amount of tracer per well. We also optimized the amount of solid phase by varying the amounts of avidin and of MAL 5-biotin, keeping the amount of tracer constant. Typically, we used, per well, 2 pg of acetyl-avidin, 0.5 pg of MAL 5-biotin, and 10 pU of immunocomplex tracer. Figure 2 shows three typical dose-response curves obtained with the Bi-EIA and the reference EIAs with use of the same capture antibody (MAL 5) and, as tracer, the hLH-specific antibody MAL 1 coupled to 13-r-galactosidase at two different enzymatic activities. We calibrated at 10 pU per well the enzymatic activities of both the reagents (BiAb/13-gal and MAL 1/ f3-D-galactosidase) to compare the relative efficiencies of the two systems.
We also compared EIA with Bi-EIA, using the tracer MAL 1/13-o-galactosidase at an enzymatic activity of 20 U per well, which gives maximal sensitivity as previously described (10). As can be seen, the curve obtained with the BiAb/f3-gal shows better resolution between different concentrations of the ligand. The detection limit for hLH, defined as the concentration giving the zero signal + 3 SD (Table 1) . We determined the intraasaayCV for the Bi-EIA by analyzing three serum samples with different concentrations of hLH, in 10 replicates, in the same run. The unterassay CV was estimated by determining hLH in serum samples at three concentrations on 10 different occasions.
Linearity. We assessed the linearity of Bi-EIA by diluting one serum pool with assay buffer in the following ratios: 1:2, 1:4, 1:8, and 1:16. We measured the hLH concentration in the undiluted sample, from which we calculated the expected values of the diluted samples. 
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Cross-reactivity.
The specificity of the Bi-EIA, EIA, and hLH assay was assessed by incubating with immunochemical-grade human follotropin (NIBSC 83/575) in amounts up to 100 int. units/mL, human thyrotropin (2nd IEP 80/558) up to 100 mt. units/mL, and human choriogonadotropin (1st IRP 75/537) up to 10 mt. units/mL. The respective croas-reactivities were as follows: #{149} Bi-EIA: 0.03%; 0.02%; <0.04% #{149} EIA: 0.02%; 0.01%; <1.2% The data show lesser cross-reactivity against hCG in the Bi-EIA than in the EJA. No high-dose inhibition of binding ("hook effect") was observed with concentrations of hLH up to 6700 int. units/L (data not shown).
The kinetics. Figure 3 shows the kinetics of the Bi-EIA and EIA and indicates that longer incubations increase the absorbance at all doses of hLH only for the Bi-EIA. The EIA reachedequilibriumafterabout 3 h. Since their first description in 1983, bi-specific antibodies obtainedfrom the hybrid hybridomas have been proposed as alternative reagents for the chemical corjugates used as tracers in iminunoenzymatic assays. However, the development of Bi-EIA immunoassays has so far encountered some problems, the major one being the difficulty of purifying to homogeneity the hybrid molecules from a mixture of different antibody species, because of the random assortment of heavy and light chains. When a mixture of monovalent and bivalent antibodies is used, the monovalent molecules can be preferentially displaced by the bivalent ones through differences in antigemc avidity. Thus, the final performance of a Bi-EIA depends greatly on the absence from the antibody preparation of parental ligand specific antibodies that can interfere with the recognition of the analyte by the tracer BiAb.
In a previous set of experiments, we tried top hybrid antibodies by both ion-exchange chromatography and high-performance chromatography on hydroxyapatite, but neither completely separated the bi-specific antibodies from the parental molecules that could interfere with final assay sensitivity. Here we describe an alternative approach to BiAb purification. Separation of BiAb//3-gal by Bio-gel HPHT (shown in Figure 1 ) generates two peaks of purified iinmunocomplexes with different enzymatic activities. The peak eluting at 77.29 mm has greater f3-D-galactosidase activity, and for this reason it was chosen for use in all subsequent experiments. Because the retention time of the peak at 77.29 mm differs only slightly from the retention time of the peak representing uncomplexed antibodies, which is likely to contain most of the monospecific antibodies, in some cases we did furtherpurification by high-performance, gel-Illtration chromatography. This step is not always necessary, because we could achieve optimal assay sensitivity with HPHT-purifled immunocomplexes as discussed below. The validity of our approach to BiAb purification was confirmed by additional experiments in which the purified immunocomplexes were used as tracers in a "sandwich"-type assay.
The comparison of the standard curves obtained with the purified BiAb/f3-gal and the chemically cortjugated antibodies shows that, when the same enzymatic activity is added to the reaction, the BiAb/f3-gal generates a more intense color (F,igure 2, compare curve a with curvec), with a better discrimination between different concentrations. The difference between the two reagents is even more evident in the kinetics of the reaction at low concentration of the analyte (Figure 3) . In this experiment, two reagents differing in total enzymatic activity (10 U per well for the BiAb/3-gal vs 20 U per well for the conjugate) were compared and the immunocomplexes gave four to five times greater absorbance values than those obtained with the conjugate.
The intra-and interassay precision, analytical recovery, and precision proffle of the Bi-EIA were also within the acceptable ranges for routine clinical immunoassays (see Tables 1 and 2 and Figure  4) . Precision, evaluated as intra-asaay variability of 25 replicates of a pool of sera, was much superior to that obtained with a commercial ELISA (Ultrascan) and comparableto that of an iRMA (MAJA Clone hLH). The working range of the assay is between 0 and 120 mt. unitsfL. This measuring range and the observed insensitivity to the high-dose hook effect would ensure accuracy of results and eliminate the need for any sample dilution. Only samples with lutropin values >120 mt. unitafL may require result validation by assay of diluted samples. Therefore, high sensitivity of the assay may be useful for determinations of hLH in subjects with hypopituitarism, during the luteal phase of the menstrual cycle, and in individuals with hyposecretory states, such as in prepubertal children. The comparison studies show that the highest correlation is that between the Bi-EIA and (a) the EJA involving the same monoclonal conjugated to /3-D-galactosidase (0.979) and (b) the IRMA (0.960).
With regard to specificity, the most relevant feature of the Bi-EIA is the low cross-reactivity with hCG (<0.04%) as compared with the cross-reactivity of the conjugated antibody (<1.2%). There is at present no definitive explanation for the lower cross-reactivity of the BiAb/f3-gal, although we can speculate that the lesser avidity of the bivalent antibody than that of the monovalent antibody results in higher epitope selectivity.
On the basis of the data presented in this paper, we conclude that bi-specific antibodies, used in the form of soluble antibody-enzyme complexes, can indeed be used as alternative reagents to trace human soluble antigens. On the basis of all generally accepted criteria for the evaluation of clinical immunoassays, the Bi-EIA is as sensitive and accurate as other commercial immunoassays.
